ARV-393

ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 is being studied to inhibit non-Hodgkin lymphoma.


Cat. No.: EX-A8806	Purity: >98%

	Chemical structure of ARV-393

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	900	In-stock
500mg	1600	In-stock
1g	2400	In-stock
2g	3900	In-stock
5g	9500	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	2851885-95-3
Purity	>98%
Formula	C46H53ClFN9O7
Mol Weight	898.421
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 years, protect from light; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin's Lymphoma[J]. Cancer Research, 2024, 84(7_Supplement): ND05-ND05. [2]. Paolo F. Caimi, et al. Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood. 2024, 144: 6505. [3]. Paolo Caimi, et al. Abstract PO-010: Trial in Progress: Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood Cancer Discov. 2024. 5 (3_Supplement): PO-010.
Data Sheet	Data sheet of ARV-393
CoA	CoA of ARV-393
SDS	SDS of ARV-393


		Search